Occult prostate cancer in men with low serum testosterone levels

被引:193
作者
Morgentaler, A
Bruning, CO
DeWolf, WC
机构
[1] Division of Urology, Beth Israel Hospital, Harvard Medical School, Boston, MA
[2] Division of Urology, Beth Israel Hospital, Boston, MA 02215
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1996年 / 276卷 / 23期
关键词
D O I
10.1001/jama.276.23.1904
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To determine the prevalence of occult prostate cancer in men with low serum total testosterone or free testosterone levels. Design.-Retrospective analysis of a consecutive series of men. Setting.-Academic teaching hospital. Patients.-Seventy-seven men with low total testosterone or free testosterone levels, with normal results of digital rectal examination and prostate-specific antigen (PSA) levels of 4.0 ng/mL or less. The mean age was 58 years. Interventions.-Sextant prostate needle biopsies with ultrasound guidance. Main Outcome Measures.-Results of prostate needle biopsies, transrectal ultrasound, prostate volume, PSA level, PSA density, total and free testosterone levels. Results.-Prostate cancer was identified in 14% (11/77) of the entire group and in 10 men (29%) aged 60 years or older. The median age for men with cancer was 64 years. Histologic examination showed Gleason scores of 6 or 7 for all cancers. No significant differences were noted between the cancer and benign groups with regard to PSA level, PSA density, prostate volume, total testosterone level, or free testosterone level. Conclusions.-A high prevalence of biopsy-detectable prostate cancer was identified in men with low total or free testosterone levels despite normal PSA levels and results of digital rectal examination. These data suggest that (1) digital rectal examination and PSA levels are insensitive indicators of prostate cancer in men with low total or free testosterone levels, and (2) PSA levels may be altered by naturally occurring reductions in serum androgen levels.
引用
收藏
页码:1904 / 1906
页数:3
相关论文
共 24 条
[1]  
BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341
[2]   LATENT CARCINOMA AND ATYPICAL LESIONS OF PROSTATE - AN AUTOPSY STUDY [J].
BILLIS, A .
UROLOGY, 1986, 28 (04) :324-329
[3]   ASSAY VARIABILITY IN SERUM PROSTATE-SPECIFIC ANTIGEN DETERMINATION [J].
BRAWER, MK ;
DAUM, P ;
PETTEWAY, JC ;
WENER, MH .
PROSTATE, 1995, 27 (01) :1-6
[4]   MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
DODDS, KM ;
COPLEN, DE ;
YUAN, JJJ ;
PETROS, JA ;
ANDRIOLE, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1156-1161
[5]   PROSTATE-CANCER DETECTION IN A CLINICAL UROLOGICAL PRACTICE BY ULTRASONOGRAPHY, DIGITAL RECTAL EXAMINATION AND PROSTATE SPECIFIC ANTIGEN [J].
COONER, WH ;
MOSLEY, BR ;
RUTHERFORD, CL ;
BEARD, JH ;
POND, HS ;
TERRY, WJ ;
IGEL, TC ;
KIDD, DD .
JOURNAL OF UROLOGY, 1990, 143 (06) :1146-1154
[6]   DIAGNOSIS OF PROSTATIC-CARCINOMA - THE YIELD OF SERUM PROSTATE-SPECIFIC ANTIGEN, DIGITAL RECTAL EXAMINATION AND TRANSRECTAL ULTRASONOGRAPHY [J].
ELLIS, WJ ;
CHETNER, MP ;
PRESTON, SD ;
BRAWER, MK .
JOURNAL OF UROLOGY, 1994, 152 (05) :1520-1525
[7]  
ENGLISH HF, 1986, CANCER RES, V46, P839
[8]  
Gleason DF., 1977, UROLOGIC PATHOLOGY P
[9]  
GUESS HA, 1993, UROL CLIN N AM, V20, P627
[10]   PROSTATE-CANCER IN NONUROLOGICAL PATIENTS WITH NORMAL PROSTATES ON DIGITAL RECTAL EXAMINATION [J].
HAMMERER, P ;
LOY, V ;
DIERINGER, J ;
HULAND, H .
JOURNAL OF UROLOGY, 1992, 147 (03) :833-836